Ypsomed is the leading developer and manufacturer of self-injection systems for liquid medications, offering the most comprehensive and innovative platform portfolio for pens, autoinjectors, and on-body devices.
Our products and solutions
We offer a wide range of injection systems, digital health solutions, and future-focused innovations for pharma clients.
As the reliable partner of pharmaceutical and biotech companies for more than 40 years, Ypsomed provides tailored selfcare solutions to meet specific needs. Delivered with best-in-class execution and ready to integrate with digital health services, these solutions help simplify therapy and improve the quality of life for millions of people living with chronic conditions.
Our platform ecosystem combines industrialized drug delivery technology with a set of built-in and optional services that support every stage of development.
Ypsomed enhances self-injection device platforms with integrated human factors services
Streamline clinical development with Ypsomed
Clear to Clinic
Clinic-ready devices to accelerate trial readiness and reduce study risk Speed defines success in clinical development. Participant recruitment constraints, lengthy dose-finding protocols, and device bridging timelines create critical delays. Clear to Clinic enables the use of clinic-ready YpsoMate 1 mL and YpsoMate 2.25 mL autoinjectors in clinical trials to accelerate, simplify and derisk your program.
Burgdorf, 20.05.2026, 07:00 a.m. – Ypsomed (SIX: YPSN) closed the financial year 2025/26 with consolidated revenue of CHF 731.0 million (prior year: CHF 748.9 million). Delivery Systems, the Company's core business segment, reported revenue of CHF …
The development of drug-device combination products continues to evolve, with increasing attention on how clinical bridging between different delivery systems is handled. In this context, regulatory approaches that support more efficient and …
The Pre-Filled Syringes and Injectable Drug Devices West Coast Conference returns to San Diego in June, bringing pharma, biotech, and device experts together to advance combination product development.
Drug-Device Combination Products for Parenteral Use
A focused event on drug-device combination products at the Novartis Campus in Basel brings together experts across research, development and manufacturing, with Ypsomed's Jakob Lange contributing to a panel on high-volume injections.
HLTH Europe returns to Amsterdam, bringing together 5,000+ leaders from across the healthcare ecosystem to connect, exchange ideas, and engage with key decision-makers in one place.
We pursue a long-term corporate strategy based on four pillars. These four pillars stand for areas of action in which we fulfill our responsibility to society as a sustainably oriented company.
We are committed to acting responsibly towards our employees, our partners and society. We are also committed to the circular economy and reducing our carbon footprint.